FindTrial
Sign In

Study to quantify the benefits of adaptive radiotherapy in PET-CT based radiotherapy planning on patients of lung cancer

Quantification of dosimetric benefits of adaptive radiotherapy in PET/CT versus CT based radiotherapy planning on patients of stage III non-small cell lung cancer receiving concurrent chemoradiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/10/016171
Enrollment
15
Registered
2018-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung

Interventions

Intervention1: NIL: NIL

Sponsors

Dr Namrata Das
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pathologically confirmed non small cell lung cancer Stage III confirmed by FDG PET-CT ECOG performance status 0 or 1

Exclusion criteria

Exclusion criteria: Other neoplasm in the last 5 years Uncontrolled comorbidities like DM, HTN, TB Pregnant or breastfeeding mother Contradictions for cisplatin

Design outcomes

Secondary

MeasureTime frame
Doses received by the organs at risk: Lung V20: Volume of lung receiving 20 Gy Spinal Cord Dmax: Maximum dose at a point in the tissue Heart Dmean: Mean dose received by the heart Timepoint: 6 weeks—

Primary

MeasureTime frame
D98 (Dose received by 98% of the Planning Target Volume) of Treatment Arm and Dosimetric ArmTimepoint: 6 weeks—

Countries

India

Contacts

Public ContactDr Namrata Das

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

drkapoor.r@gmail.com9872648344

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026